- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,863
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson's Disease
- Interventions
- TNM Device
- Device
- Lead sponsor
- Scion NeuroStim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Parkinson's Disease, Multiple System Atrophy
- Interventions
- Not listed
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Tauopathies
- Interventions
- 18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
- Drug · Diagnostic Test · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- San Francisco, California • Philadelphia, Pennsylvania
- Conditions
- Parkinson Disease
- Interventions
- Bicycling with and without virtual reality
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Newark, New Jersey • Old Westbury, New York
- Conditions
- Parkinson Disease
- Interventions
- LBT-3627, Immunological profiling
- Diagnostic Test
- Lead sponsor
- Longevity Biotech
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Healthy
- Interventions
- (11C)PE2I, Ioflupane
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 20 Years to 100 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Parkinson's Disease
- Interventions
- Deep Brain Stimulation
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Parkinson's Disease
- Interventions
- P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
- Drug
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 21 more
- Conditions
- Parkinsons Disease, Lewy Bodies Disease
- Interventions
- Armodafinil
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 50 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Levodopa-Induced Dyskinesia, Parkinson's Disease
- Interventions
- Intervention: Ketamine
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Cough, Parkinson's Disease
- Interventions
- Capsaicin, Voluntary cough test
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- Parkinson Disease, Accidental Falls
- Interventions
- Vitamin D3, calcium, Placebo
- Drug · Dietary Supplement · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Parkinson Disease
- Interventions
- Botulinum Toxin Type A, Placebo
- Biological
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Anxiety Disorders, Parkinson Disease
- Interventions
- rotigotine transdermal patch, placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Early Stage Parkinson Disease
- Interventions
- Pardaprunox, pramipexole, Placebo Comparator
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
- Conditions
- Parkinson Disease, Cognitive Dysfunction
- Interventions
- SAGE-718-matching placebo, SAGE-718
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 38
- States / cities
- Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 33 more
- Conditions
- Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
- Interventions
- Boserolimab, Pembrolizumab, Pemetrexed, Carboplatin, Nab-paclitaxel
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Mobile, Alabama • Sarasota, Florida • Germantown, Tennessee
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Favezelimab, Lenvatinib, Quavonlimab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Tempe, Arizona • Sacramento, California • San Francisco, California + 15 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
- Conditions
- Parkinson Disease, Idiopathic, Parkinson Disease
- Interventions
- Deep brain stimulation
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Parkinsonian Syndromes
- Interventions
- 123 I - ALTROPANE®
- Drug
- Lead sponsor
- Alseres Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Hopkinton, Massachusetts
- Conditions
- Parkinson's Disease
- Interventions
- Rasagiline, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 34 more
- Conditions
- Parkinson's Disease
- Interventions
- Ketamine, Remimazolam
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California